References

Ahmadzadehfar H (2016) Targeted therapy for metastatic prostate cancer with radionuclides. In:

Mohan R (ed) Prostate cancer – leading-edge diagnostic procedures and treatments

Ahmadzadehfar H, Rahbar K, Kurpig S, Bogemann M, Claesener M, Eppard E et al (2015) Early

side effects and first results of radio ligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-

resistant metastatic prostate cancer: a two-centre study. EJNMMI Res 5:114. https://doi.org/10.

1186/s13550-015-0114-2

Ahmadzadehfar H, Eppard E, Kürpig S, Fimmers R, Yordanova A, Schlenkhoff CD, Gärtner F,

Rogenhofer S, Essler M (2016) Therapeutic response and side effects of repeated radioligand

therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer.

Oncotarget 7(11):12477

Ahmadzadehfar H, Rahbar K, Essler M, Biersack HJ (2020) PSMA-based theranostics: a step-by-

step practical approach to diagnosis and therapy for mCRPC patients. Semin Nucl Med 50:98–

109. https://doi.org/10.1053/j.semnuclmed.2019.07.003

Alzahrani AS, AlShaikh O, Tuli M, Al-Sugair A, Alamawi R, Al-Rasheed MM (2012) Diagnostic

value of recombinant human thyrotropin–stimulated 123I whole-body scintigraphy in the

follow-up of patients with differentiated thyroid cancer. Clin Nucl Med 37(3):229–234

Are C, Rajaram S, Are M, Raj H, Anderson BO, Chaluvarya Swamy R, Vijayakumar M, Song T,

Pandey M, Edney JA, Cazap EL (2013) A review of global cancer burden: trends, challenges,

strategies, and a role for surgeons. J Surg Oncol 107(2):221–226

Ashwathanarayana AG, Biswal CK, Sood A, Parihar AS, Kapoor R, Mittal BR (2017) Imaging-

guided use of combined 177Lu-DOTATATE and capecitabine therapy in metastatic mediastinal

paraganglioma. J Nucl Med Technol 45(4):314–316

Baum RP, Kulkarni HR (2012) THERANOSTICS: from molecular imaging using Ga-68 labeled

tracers and PET/CT to personalized radionuclide therapy-the Bad Berka experience.

Theranostics 2(5):437

Baum RP, Prasad V, Hommann M, Hörsch D (2008) Receptor PET/CT imaging of neuroendocrine

tumors. In: PET in oncology. Springer, Berlin, Heidelberg, pp 225–242

Fig. 7.5 68Ga-Pentixafor

PET image in a 58-year-old

female patient with intense

tracer uptake

(SUVmax ¼ 7.9)

demonstrating recurrence in

the region of the central

primary GBM tumor

106

B. Singh et al.